cagrilintide fda Novo Nordisk Submits CagriSema for FDA Approval for Obesity Treatment Cagrilintide (AM833) - Phoenix Peptide

tirzepatide activates the GIP and GLP-1 incretin receptors and adds a glucose-dependent insulin-secretion effect that an amylin analog does not have

This product is not classified as a drug or supplement

Cagrilintide is a long-acting analog of amylin (islet amyloid polypeptide), a pancreatic hormone co-secreted with insulin that induces satiety

Cagrilintides longer measured half-life (roughly 78 days versus about 5 days for tirzepatide) is a pharmacokinetic fact from its own study not evidence of a better outcome

Product documentation may include identity, purity, and related analytical reference information depending on batch and product format